Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCELERON PHARMA INCXLRN · Entity 15780 | Director | January 25, 2019 | January 29, 2019 |
| Alkermes plc.ALKS · Entity 2392 | Director · Director and CEO, Alkermes plc | March 02, 2026 | March 05, 2026 |
| Epizyme, Inc.EPZM · Entity 12703 | Director | May 29, 2020 | June 02, 2020 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCELERON PHARMA INC
Report date January 25, 2019 · Filed January 29, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,500 |
Reported balance
After 2019-01-25 transaction · row 1
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 1,250 · Balance 32,500 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 · Expires 2029-01-25 | Direct | 7,500 |
Reported balance
After 2019-01-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-25 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date.
Alkermes plc.
Report date March 02, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 88,843 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 88,843 · Balance 88,843 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the restricted stock unit award vest in full on 12/31/2026 in connection with the Company's previously announced leadership transition.
Epizyme, Inc.
Report date May 29, 2020 · Filed June 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.55 · Expires 2030-05-28 | Direct | 14,013 |
Reported balance
After 2020-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-29 · Grant · Acquired 14,013 · Balance 14,013 F1: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 03, 2017 Filed May 5, 2017 17:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-030239 · doc4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 17:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 952 | $53.37 | $50,808.24 |
DisclosureSEC source: 0001209191-17-030239 · doc4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,512 F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| May 03, 2017 Filed May 5, 2017 17:27 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $3.40 | $51,000.00 |
DisclosureSEC source: 0001209191-17-030239 · doc4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the May 03, 2017 market close price ($53.57), and this net amount ($50.17) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 14,048 shares to the optionee. The 952 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 13,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010470 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Ordinary Shares · 13,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 6,117 | $60.97 | $372,953.49 |
DisclosureSEC source: 0001127602-17-010470 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,406 Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 22:47 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-010470 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 22:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001179110-17-004599 · edgar.xml · derivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-03-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| March 02, 2017 Filed Mar 14, 2017 22:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004599 · edgar.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 17,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009862 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Ordinary Shares · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:17 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 8,234 | $59.71 | $491,652.14 |
DisclosureSEC source: 0001127602-17-009862 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,523 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:17 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009862 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:50 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008689 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:50 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 4,705 | $52.98 | $249,270.90 |
DisclosureSEC source: 0001127602-17-008689 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,257 Read SEC document |
| February 26, 2017 Filed Feb 27, 2017 22:50 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-008689 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 22:55 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $54.57 | $0.00 |
DisclosureSEC source: 0001127602-17-007477 · form4.xml · derivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Ordinary Shares · 200,000 shares Expires 2027-02-17 F2 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/17/18. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 22:55 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007477 · form4.xml · derivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires not disclosed F1 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F1 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 22:14 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-16-068676 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,000 shares Expires 2016-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 22:14 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,050 | $57.72 | $118,320.47 |
DisclosureSEC source: 0001127602-16-068676 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,962 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.49 to $57.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 22:14 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 27,950 | $56.93 | $1,591,148.78 |
DisclosureSEC source: 0001127602-16-068676 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,012 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.47 to $57.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 29, 2016 Filed Nov 30, 2016 22:14 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 30,000 | $14.38 | $431,400.00 |
DisclosureSEC source: 0001127602-16-068676 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:05 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-16-068175 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2016-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:05 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 6,885 | $59.44 | $409,217.55 |
DisclosureSEC source: 0001127602-16-068175 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,962 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.17 to $59.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:05 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 23,115 | $58.43 | $1,350,718.09 |
DisclosureSEC source: 0001127602-16-068175 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,847 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.15 to $59.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel Read SEC document |
| November 22, 2016 Filed Nov 22, 2016 22:05 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 30,000 | $14.38 | $431,400.00 |
DisclosureSEC source: 0001127602-16-068175 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 23:07 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-16-067664 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 30,000 shares Expires 2016-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 23:07 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,060 | $59.29 | $122,133.49 |
DisclosureSEC source: 0001127602-16-067664 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,962 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.18 to $59.52. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 23:07 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 27,940 | $58.78 | $1,642,391.43 |
DisclosureSEC source: 0001127602-16-067664 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,022 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.18 to $59.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Cancel Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 23:07 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 30,000 | $14.38 | $431,400.00 |
DisclosureSEC source: 0001127602-16-067664 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.38 | $0.00 |
DisclosureSEC source: 0001127602-16-066705 · form4.xml · derivative · entry 4 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Ordinary Shares · 30,000 shares Expires 2016-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 8,946 | $53.82 | $481,465.67 |
DisclosureSEC source: 0001127602-16-066705 · form4.xml · nonDerivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,962 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.60 to $54.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 21,054 | $53.05 | $1,116,996.81 |
DisclosureSEC source: 0001127602-16-066705 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,908 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.60 to $53.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 30,000 | $14.38 | $431,400.00 |
DisclosureSEC source: 0001127602-16-066705 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 20:02 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064535 · form4.xml · derivative · entry 3 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represented a contingent right to receive one ordinary share of Alkermes plc. F2 · derivative.exercise_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. F2 · derivative.expiration_date: This performance restricted stock unit, which was granted to the reporting person on March 3, 2014, is fully vested in accordance with its terms. Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 20:02 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 9,410 | $46.43 | $436,906.30 |
DisclosureSEC source: 0001127602-16-064535 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 608,962 Read SEC document |
| October 05, 2016 Filed Oct 7, 2016 20:02 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-064535 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 618,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.